ORYZON to present vafidemstat efficacy data at the 7th World Congress on ADHD in Lisbon
MADRID, SPAIN and CAMBRIDGE MA.
• Efficacy data from the REIMAGINE Phase IIa basket trial’s Attention Deficit Hyperactivity Disorder (ADHD) cohort
• Second positive report of vafidemstat in a human CNS indication
• Company announces decision to pursue further development of vafidemstat in psychiatric indications
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces that the company will be presenting additional human efficacy data with its CNS epigenetic drug vafidemstat. Specifically, Oryzon will present data from its Phase IIa clinical trial REIMAGINE at the 7th World Congress on ADHD that will be held from Apr 25 – 28 at the Lisbon Congress Center, Lisbon, Portugal.